Zoekresultaten - 6 results
Interim analysis of COVID-19 vaccine effectiveness against hospitalisation and death using electronic health records in six European countries
mostly ≤50% between April 2022 and March 2023 in all age groups (with a few point estimates >50%). It waned 12 weeks after administration and dropped even lower after 24 weeks. In the most recent ...
Vaccine effectiveness of the second and third COVID-19 boosters in Belgium (administered during 2022 autumn campaign)
people working in the healthcare sector and those living in nursing homes in all regions of Belgium. From the 12th of September 2022 onwards, the Interministerial Conference (IMC) organised an autumn ...
Characterisation of tetanus monoclonal antibodies as a first step towards the development of an in vitro vaccine potency immunoassay.
cell-based neutralisation assay to support prior in vivo potency data that was available for some, but not all, of the antibodies. In addition, antibody affinity was measured, and epitope competition analysis ...
Characterisation of diphtheria monoclonal antibodies as a first step towards the development of an in vitro vaccine potency immunoassay.
identify pairs of antibodies that could be deployed in a sandwich immunoassay format. Not all characterisation tests provided evidence of “superiority” of one mAb over another, but together the results from ...
Regulatory issues regarding manufacture and control of vaccine adjuvants. The EU situation.
Future Development, Meeting Management, Issue Herriot,J., Vanden Bossche,G., Lausanne, Switserland (2013) Keywords: a Activity additional ALL Aluminium an Antioxidant Antioxidants application AS assessment ...
Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting.
DNA-primed-protein-boosted animals, compared to those that received only the DNA vaccination. Moreover, these responses appeared to be better sustained over time. Antibodies were readily produced by all three methods of ...